A peptidomimetic inhibitor of matrix metalloproteinases containing a tetherable linker group

Journal of Biomedical Materials Research - Part A

Volumn 96 A, Issue 4, 2011, Pages 663-672

  Cao, Yang ^a   Croll, Tristan I ^a   Rizzi, Simone C ^a   Shooter, Gary K ^a   Edwards, Helen ^a   Finlayson, Kathleen ^a   Upton, Zee ^a   Dargaville, Tim R ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

chronic wound fluid; hydrogel; hydroxamic acid; matrix metalloproteinase inhibitor; polyethylene glycol

Indexed keywords

CHRONIC WOUND FLUID; CHRONIC WOUNDS; CONNECTIVE TISSUES; EXTRACELLULAR MATRICES; FACILE REACTION; HYDROXAMIC ACIDS; LINKER GROUPS; MATRIX METALLOPROTEINASE INHIBITOR; MATRIX METALLOPROTEINASES; METALLOPROTEINASES; MMP INHIBITOR; NATURAL TISSUES; OVER-EXPRESSION; PEPTIDOMIMETICS; PROTEOLYTIC ACTIVITIES; PSEUDO-PEPTIDE; REBALANCING; STANDARD SOLUTIONS; WOUND REPAIR;

BLOOD VESSELS; ENZYME ACTIVITY; ENZYME INHIBITION; FLUIDS; MUSCULOSKELETAL SYSTEM; ORGANIC ACIDS; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; POLYETHYLENES; THERMOPLASTICS; TISSUE;

HYDROGELS;

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROGOL; MATRIX METALLOPROTEINASE; PEPTIDOMIMETIC AGENT; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; CHRONIC DISEASE; CHRONIC WOUND; CONNECTIVE TISSUE; DIFFUSION; EXTRACELLULAR MATRIX; HYDROGEL; IC 50; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SOLUTION AND SOLUBILITY; ULCER; WOUND HEALING;

ENZYME ACTIVATION; HUMANS; HYDROGELS; ISOENZYMES; MATRIX METALLOPROTEINASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PEPTIDOMIMETICS; POLYETHYLENE GLYCOLS; PROTEIN CONFORMATION;

EID: 79551688936     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.33027     Document Type: Article

References (38)

1. Page-McCaw A, Ewald AJ, Werb Z,. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev 2007; 8: 221-233.
2. Nagase H, Visse R, Murphy G,. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-573.
3. Parks WC, Wilson CL, Lõpez-Boado YS,. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev 2004; 4: 617-622.
4. Gearing AJH, Thorpe SJ, Miller K, Mangan M, Varley PG, Dudgeon T, Ward G, Turner C, Thorpe R,. Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin. Immunol Lett 2002; 81: 41-48.
5. Levi E, Fridman R, Miao HQ, Ma YS, Yayon A, Vlodavsky I,. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 1996; 93: 7069-7074.
6. McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, Clark-Lewis I, Overall CM,. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem. 2001; 276: 43503-43508.
7. Nagase H, Murphy G,. Tailoring TIMPs for selective matalloproteinase inhibition. In:, Edwards D, editor. The Cancer Degradome: Proteases and Cancer Biology. Cambridge: Springer Science; 2008. p 787-812.
8. Ravanti L, Kähäri V-M,. Matrix metalloproteinases in wound repair (Review). Int J Mol Med 2000; 6: 391-407.
9. Rayment EA, Upton Z, Shooter GK,. Increased matrix metalloproteinase-9 (MMP-9) activity observed in chronic wound fluid is related to the clinical severity of the ulcer. Br J Dermatol 2008; 158: 951-961.
10. Yager DR, Nwomeh BC,. The proteolytic environment of chronic wounds. Wound Repair Regen 1999; 7: 433-441.
11. Cullen B, Smith R, Mcculloch E, Silcock D, Morrison L,. Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair Regen 2002; 10: 16-25.
12. Edwards JV, Howley P, Cohen IK,. In vitro inhibition of human neutrophil elastase by oleic acid albumin formulations from derivatized cotton wound dressings. Int J Pharm 2004; 284: 1-12.
13. Schönfelder U, Abel M, Wiegand C, Klemm D, Elsner P, Hipler U,. Influence of selected wound dressings on PMN elastase in chronic wound fluid and their antioxidative potential in vitro. Biomaterials 2005; 26: 6664-6673.
14. Upton Z, Cuttle L, Noble A, Kempf M, Topping G, Malda J, Xie Y, Mill J, Harkin DG, Kravchuk O, Leavesley DI, Kimble RM,. Vitronectin: Growth factor complexes hold potential as a wound therapy approach. J Invest Dermatol 2008; 128: 1535-1544.
15. Coussens LM, Fingleton B, Matrisian LM,. Cancer therapyâMatrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 2002; 295: 2387-2392.
16. Peterson JT,. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004; 9: 63-79.
17. Peterson JT,. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res 2006; 69: 677-687.
18. Hesek D, Toth M, Meroueh SO, Brown S, Zhao H, Sakr W, Fridman R, Mobashery S,. Design and characterisation of a metalloproteinase inhibitor-tethered resin for the detection of active MMPs in biological samples. Chem Biol 2006; 13: 379-386.
19. Skarja GA, Brown AL, Ho RK, May MH, Sefton MV,. The effect of a hydroxamic acid-containing polymer on active matrix metalloproteinases. Biomaterials 2009; 30: 1890-1897.
20. Whittaker M, Floyd CD, Brown P, Gearing AJH,. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999; 99: 2735-2776.
21. Elbert DL, Pratt AB, Lutolf MP, Halstenberg S, Hubbell JA,. Protein delivery from materials formed by self-selective conjugate addition reactions. J Controlled Release 2001; 76: 11-25.
22. Beekman B, Drijfhout JW, Bloemhoff W, Ronday HK, Tak PP, Koppele JMT,. Convenient fluorometric assay for matrix metalloproteinase activity and its application in biological media. FEBS Lett 1996; 390: 221-225.
23. Fernandez ML, Broadbent JA, Shooter GK, Malda J, Upton Z,. Development of an enhanced proteomic method to detact prognostic and diagnostic markers of healing in chronic wound fluid. Br J Dermatol 2008; 158: 281-290.
24. Seebeck B, Reulecke I, Kämper A, Rarey M,. Modeling of metal interaction geometries for protein-ligand docking. Proteins 2008; 71: 1237-1254.
25. Feng YQ, Likos JJ, Zhu LM, Woodward H, Munie G, McDonald JJ, Stevens AM, Howard CP, De Crescenzo GA, Welsch D, et al. Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor. Biochim Biophys Acta: Proteins Proteomics 2002; 1598: 10-23.
26. Brown PD, Davidson AH, Drummond AH, Gearing A, Whittaker M,. Hydroxamic acid matrix metalloproteinase inhibitors. In:, Clendeninn NJ, Appelt K, editors. Matrix Metalloproteinase Inhibitors in Cancer Therapy. Totowa, New Jersey: Humana Press; 2001. p 113-142.
27. Parks WC,. Matrix metalloproteinases in repair. Wound Repair Regen 1999; 7: 423-432.
28. Iskander GM, Kapfenstein HM, Davis TP, Wiley DE,. Synthesis and copolymerization of methacryloyl hydroxamic acids. J Appl Polym Sci 2000; 78: 751-758.
29. Taira J, Miyagi C, Aniya Y,. Dimerumic acid as an antioxidant from the mold. Monascus anka: The inhibition mechanisms against lipid peroxidation and hemeprotein-mediated oxidation. Biochem Pharmacol 2002; 63: 1019-1026.
30. Lutolf MP, Hubbell JA,. Synthesis and physicochemical characterization of end-linked poly(ethylene glycol)-co-peptide hydrogels formed by Michael-type addition. Biomacromolecules 2003; 4: 713-722.
31. Hern DL, Hubbell JA,. Incorporation of adhesion peptides into nonadhesive hydrogels useful for tissue resurfacing. J Biomed Mater Res 1998; 39: 266-276.
32. Peppas NA, Bures P, Leobandung W, Ichikawa H,. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm 2000; 50: 27-46.
33. Raeber GP, Lutolf MP, Hubbell JA,. Molecularly engineered PEG hydrogels: A novel model system for proteolytically mediated cell migration. Biophys J 2005; 89: 1374-1388.
34. Morgunova E, Tuuttila A, Bergmann U, Tryggvason K,. Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. Proc Natl Acad Sci USA 2002; 99: 7414-7419.
35. Lutolf MP, Lauer-Fields JL, Schmoekel HG, Metters AT, Weber FE, Fields GB, Hubbell JA,. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: Engineering cell-invasion characteristics. Proc Natl Acad Sci USA 2003; 100: 5413-5418.
36. Rizzi SC, Ehrbar M, Halstenberg S, Raeber GP, Schmoekel HG, Hagenmuller H, Muller R, Weber FE, Hubbell JA,. Recombinant protein-co-PEG networks as cell-adhesive and proteolytically degradable hydrogel matrixes. II. Biofunctional characteristics. Biomacromolecules 2006; 7: 3019-3029.
37. Stotts NA, Rodeheaver GT, Thomas DR, Frantz RA, Bartolucci AA, Sussman C, Ferrell BA, Cuddigan J, Maklebust J,. An instrument to measure healing in pressure ulcers: development and validation of the pressure ulcer scale for healing (PUSH). J Gerontol Biol Sci Med Sci 2001; 56, M795-M799.
38. Broadbent J, Walsh T, Upton Z,. Proteomics in chronic wound research: Potentials in healing and health. Proteom Clin Appl 2010; 4: 204-214.